251 – 329 of 329
- show: 250
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- « previous
- 1
- 2
- next »
- 2003
-
Mark
The pharmacokinetics of clotting factor therapy.
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
-
Mark
Experience with a new percutaneous port system, Percuseal(R), for intravenous injection in patients with haemophilia, von Willebrand disease and severe alpha1-antitrypsin deficiency.
(
- Contribution to journal › Article
-
Mark
Prophylactic therapy for haemophilia: early experience.
(
- Contribution to journal › Article
-
Mark
On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
A Healthy Hemophilic Patient without Arthropathy: From Concept to Clinical Reality.
(
- Contribution to journal › Article
-
Mark
Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?
(
- Contribution to journal › Article
-
Mark
Elective orthopaedic surgery for inhibitor patients.
(
- Contribution to journal › Article
-
Mark
Tailored pharmacokinetic dosing allows self-administration and reduces the cost of IV augmentation therapy with human alpha(1)-antitrypsin.
(
- Contribution to journal › Article
-
Mark
Limited protective effect of the CCR5 Delta 32/CCR5 Delta 32 genotype on human immunodeficiency virus infection incidence in a cohort of patients with hemophilia and selection for genotypic X4 virus
(
- Contribution to journal › Article
-
Mark
Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population
(
- Contribution to journal › Article
- 2002
-
Mark
Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients
(
- Contribution to journal › Article
-
Mark
Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen
(
- Contribution to journal › Article
-
Mark
The prognostic value of global haemostatic tests in the intensive care unit setting.
(
- Contribution to journal › Article
-
Mark
Clinical outcomes and resource utilization associated with haemophilia care in Europe
(
- Contribution to journal › Article
-
Mark
Progress in haemophilic care: ethical issues.
(
- Contribution to journal › Article
-
Mark
Unresolved issues in prophylaxis
(
- Contribution to journal › Article
-
Mark
Antibodies to factor VIIa in patients with haemophilia and high-responding inhibitors.
(
- Contribution to journal › Article
- 2001
-
Mark
The Malmo International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients
(
- Contribution to journal › Article
-
Mark
Anti- and procoagulant activities in factor VII-deficient subjects
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction: recombinant vs. human-derived product
(
- Contribution to journal › Article
-
Mark
Therapeutic choices for patients with hemophilia and high-titer inhibitors
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
An approach to study the viral safety of plasma-derived products in previously treated, non-infected patients
(
- Contribution to journal › Article
-
Mark
Clinical spectrum of hepatitis C-related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease
(
- Contribution to journal › Article
-
Mark
No increased risk of venous thrombosis in women taking tranexamic acid
(
- Contribution to journal › Letter
-
Mark
The concern of viral safety in the treatment of hemophilia
(
- Contribution to journal › Article
-
Mark
Hormone replacement therapy in healthy postmenopausal women: a randomized, placebo-controlled study of effects on coagulation and fibrinolytic factors
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia
(
- Contribution to journal › Scientific review
-
Mark
The clinical importance of correctly diagnosing venous thrombosis
(
- Contribution to journal › Article
-
Mark
Symposium in memory of Professor Inga Marie Nilsson
(
- Contribution to journal › Published meeting abstract
-
Mark
Byte från Prothromplex till Beriplex P/N som akut antidot mot warfarin
(
- Contribution to journal › Article
- 2000
-
Mark
Effect kinetics of desmopressin-induced platelet retention in healthy volunteers treated with aspirin or placebo
(
- Contribution to journal › Article
-
Mark
Correlation between different intensities of anti-vitamin K treatment and coagulation parameters
(
- Contribution to journal › Article
-
Mark
NovoSeven in warfarin-treated patients
(
- Contribution to journal › Article
-
Mark
Använd hela "analyspaketet" vid utredning av trombospatienten! Och glöm inte släktingarna ...
(
- Contribution to journal › Article
-
Mark
Impact, diagnosis and treatment of von Willebrand disease
(
- Contribution to journal › Article
-
Mark
Immune tolerance induction and the treatment of hemophilia. Malmo protocol update
(
- Contribution to journal › Article
-
Mark
The optimal treatment for haemophiliacs who have developed factor VIII or -IX antibodies
(
- Contribution to journal › Article
-
Mark
Replik: Behandlingstiden har effekter och bieffekter
(
- Contribution to journal › Article
-
Mark
Recombinant FVIIa in the treatment of warfarin bleeding
(
- Contribution to journal › Article
-
Mark
Molecular genetic analysis of severe protein C deficiency
(
- Contribution to journal › Article
-
Mark
Regimens of factor VIII administration--continuous infusion vs. bolus
(
- Contribution to journal › Article
-
Mark
The Malmo model for immune tolerance induction: impact of previous treatment on outcome
(
- Contribution to journal › Article
- 1999
-
Mark
Changes in levels of factor VII and protein S after acute myocardial infarction: effects of low-dose warfarin
(
- Contribution to journal › Article
-
Mark
Progression of retinopathy after improved metabolic control in type 2 diabetic patients. Relation to IGF-1 and hemostatic variables
(
- Contribution to journal › Article
-
Mark
Centraliserad vård grundläggande i vårdprogram för blödarsjuka
(
- Contribution to journal › Article
-
Mark
Nya rön om behandling av djup ventrombos: Behandlingstidens längd föremål för internationella studier
(
- Contribution to journal › Article
-
Mark
Malmo International Brother Study (MIBS): an international survey of brother pairs with haemophilia
(
- Contribution to journal › Article
-
Mark
Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized
(
- Contribution to journal › Article
-
Mark
Tolerance induction using the Malmo treatment model 1982-1995
(
- Contribution to journal › Article
-
Mark
HELLP en livshotande graviditetskomplikation. Specifik koagulationsfaktorbehandling nu möjlig
(
- Contribution to journal › Article
-
Mark
Nytt system testar den mekaniska hjärtklaffen. Egenkontroll i hemmet av antivitamin K-terapin ger patienten större frihet
(
- Contribution to journal › Article
-
Mark
Factor V Q506 (resistance to activated protein C) and prognosis after acute coronary syndrome
(
- Contribution to journal › Article
-
Mark
Other ongoing rFVIII PUP studies
(
- Contribution to journal › Article
- 1998
-
Mark
Multidose pharmacokinetics of factor IX: implications for dosing in prophylaxis
(
- Contribution to journal › Article
-
Mark
Immunoadsorption for removal of inhibitors: update on treatments in Malmo-Lund between 1980 and 1995
(
- Contribution to journal › Article
-
Mark
Major surgery seems not to influence HIV disease progression in haemophilia patients
(
- Contribution to journal › Article
-
Mark
Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B
(
- Contribution to journal › Article
-
Mark
Low recurrence rate after deep calf-vein thrombosis with 6 weeks of oral anticoagulation
(
- Contribution to journal › Article
-
Mark
Liposuction in Dercum's disease: impact on haemostatic factors associated with cardiovascular disease and insulin sensitivity.
(
- Contribution to journal › Article
-
Mark
The Malmo-Klaipeda WFH twinning programme: a comparative description of the haemophilia cohorts
(
- Contribution to journal › Scientific review
-
Mark
Blödarsjuka med HIV. Långsammare infektionsförlopp hos yngre och vid större förbrukning av faktorkoncentrat
(
- Contribution to journal › Article
- 1997
-
Mark
No effect of a new second-generation B-domain-deleted recombinant product on lymphocyte transformation in vitro: a study of plasma-derived and recombinant products
(
- Contribution to journal › Article
-
Mark
Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis
(
- Contribution to journal › Article
-
Mark
Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A
(
- Contribution to journal › Article
-
Mark
Age relations of cardiovascular risk factors in a traditional Melanesian society: the Kitava Study
(
- Contribution to journal › Article
- 1996
-
Mark
Prevalence of factor V gene mutation amongst myocardial infarction patients and healthy controls is higher in Sweden than in other countries
(
- Contribution to journal › Article
-
Mark
Antitrombin III-koncentrat söker sin roll i terapin. Var försiktig och invänta studieresultat!
(
- Contribution to journal › Article
- 1995
-
Mark
Resistens mot aktiverat protein C. Vanlig genetisk riskfaktor för venös trombos
(
- Contribution to journal › Article
- 1994
-
Mark
Prophylactic treatment of severe hemophilia A and B can prevent joint disability
(
- Contribution to journal › Article
-
Mark
Myocardial infarction associated with homozygous resistance to activated protein C
(
- Contribution to journal › Letter
- 1992
-
Mark
Implantable central venous catheter facilitates prophylactic treatment in children with haemophilia
(
- Contribution to journal › Article
-
Mark
Laparoscopic cholecystectomy in a patient with hemophilia B
(
- Contribution to journal › Article
- 1991
-
Mark
Antibody to a hepatitis C virus related protein among patients at high risk for hepatitis B
(
- Contribution to journal › Article
- 1990
-
Mark
Hepatitis C virus transmission by monoclonal antibody purified factor VIII concentrate
(
- Contribution to journal › Letter
-
Mark
Pyridoxine reduces cholesterol and low-density lipoprotein and increases antithrombin III activity in 80-year-old men with low plasma pyridoxal 5-phosphate
(
- Contribution to journal › Article
- « previous
- 1
- 2
- next »